{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Adenocarcinoma&page=3", "query": { "condition": "HER2 Negative Breast Adenocarcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 97, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Adenocarcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Adenocarcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T15:08:33.922Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02273752", "title": "Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "Gastrinoma", "Glucagonoma", "HER2-negative Breast Cancer", "Insulinoma", "Mucositis", "Oral Complications", "Pancreatic Polypeptide Tumor", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Islet Cell Carcinoma", "Recurrent Renal Cell Cancer", "Somatostatinoma", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2014-11", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-03", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273752" }, { "nct_id": "NCT01037790", "title": "Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Solid Tumor", "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Adult Central Nervous System Germ Cell Tumor", "Adult Teratoma", "Benign Teratoma", "Estrogen Receptor-negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "Familial Testicular Germ Cell Tumor", "HER2-negative Breast Cancer", "HER2-positive Breast Cancer", "Male Breast Cancer", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Monodermal and Highly Specialized Teratoma", "Progesterone Receptor-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Extragonadal Germ Cell Tumor", "Recurrent Extragonadal Non-seminomatous Germ Cell Tumor", "Recurrent Extragonadal Seminoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Melanoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Rectal Cancer", "Stage III Extragonadal Non-seminomatous Germ Cell Tumor", "Stage III Extragonadal Seminoma", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Ovarian Germ Cell Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Extragonadal Non-seminomatous Germ Cell Tumor", "Stage IV Extragonadal Seminoma", "Stage IV Melanoma", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Rectal Cancer", "Testicular Immature Teratoma", "Testicular Mature Teratoma" ], "interventions": [ { "name": "PD-0332991", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2009-10", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01037790" }, { "nct_id": "NCT01754519", "title": "Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ductal Breast Carcinoma In Situ", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "Invasive Cribriform Breast Carcinoma", "Invasive Ductal Carcinoma, Not Otherwise Specified", "Lobular Breast Carcinoma In Situ", "Mucinous Breast Carcinoma", "Papillary Breast Carcinoma", "Progesterone Receptor Positive", "Stage I Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIC Breast Cancer", "Tubular Breast Carcinoma" ], "interventions": [ { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2013-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-07-07", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01754519" }, { "nct_id": "NCT00640861", "title": "Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "CpG oligodeoxynucleotide", "type": "BIOLOGICAL" }, { "name": "HER-2/neu peptide vaccine", "type": "BIOLOGICAL" }, { "name": "MUC-1 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 45, "start_date": "2008-08-28", "completion_date": "2015-04-21", "has_results": false, "last_update_posted_date": "2018-10-31", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00640861" }, { "nct_id": "NCT02453620", "title": "Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Breast Adenocarcinoma", "Invasive Breast Carcinoma", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Blood Sample", "type": "OTHER" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2016-02-12", "completion_date": "2027-09-11", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 5, "location_summary": "Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453620" }, { "nct_id": "NCT06176261", "title": "DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer Female", "Metastatic Triple-Negative Breast Carcinoma", "ER Positive Breast Cancer", "HER2-negative Breast Cancer", "HER2 Negative Breast Carcinoma", "ER-negative Breast Cancer" ], "interventions": [ { "name": "Datopotamab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nancy Lin, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2024-01-08", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 3, "location_summary": "Miami, Florida • Boston, Massachusetts • Durham, North Carolina", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06176261" }, { "nct_id": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Low", "SYD-985", "SYD985", "Vic-trastuzumab Duocarmazine", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic", "HER2 Low Breast Cancer", "GastroEsophageal Cancer", "Gastroesophageal Adenocarcinoma", "Endometrium Tumor", "Ovarian Cancer", "Ovarian Carcinoma", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2 Low HR Positive", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-07-28", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04602117" }, { "nct_id": "NCT04647916", "title": "Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Metastatic HER2 Negative Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2021-06-08", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 296, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 210 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04647916" }, { "nct_id": "NCT02282345", "title": "Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Adenocarcinoma", "Deleterious BRCA1 Gene Mutation", "Deleterious BRCA2 Gene Mutation", "HER2/Neu Negative", "Invasive Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-04-16", "completion_date": "2022-06-07", "has_results": true, "last_update_posted_date": "2022-07-06", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282345" }, { "nct_id": "NCT05677802", "title": "Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Negative Breast Carcinoma", "Hormone Receptor-Negative Breast Carcinoma", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Stress Management Therapy", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2022-12-14", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-13T15:08:33.922Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Columbus, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05677802" } ] }